Maxwell Focus: Next Generation Antibiotics
Posted on June 11th, 2019
We have seen quite remarkable results of our peptoid antimicrobial drug candidates against 45 of the 47 multi-drug resistant (MDR) bacteria tested. These tests show rapid killing-kinetics against the drug resistant bacteria, in vivo biostability, rapid destruction of biofilms (a particularly tough wall that “sleeping” bacteria use to protect themselves against threats) and prevention of biofilm formation.
Our peptoid antibiotics are bioengineered to be a functional mimic of human cathelicidin antimicrobial peptide. As a synthetic mimic of pepTIDES, we call them pepTOIDS.
As a result, our board has voted to focus the company on antimicrobial peptoid drug development. We are now dedicated to following up this data with further testing of our drug candidates.
Drug Resistant bacteria
Each year in the U.S., at least 2 million people are infected with antibiotic-resistant bacteria, and at least 23,000 people die as a result. Globally, billions are infected with drug-resistant bacteria with most of the drug-resistance developing outside the US and EU, especially in India where generic antibiotic manufacturers dump surplus antibiotics into the rivers causing rapid acceleration of antibiotic resistance in that country.
No one can completely avoid the risk of resistant infections, but some people are at greater risk than others; like the elderly, children and people with chronic illnesses. When antibiotics lose their effectiveness, then we lose the ability to treat infections and control public health threats.
Many medical advances are dependent on the ability to fight infections using antibiotics, including joint replacements, organ transplants, cancer therapy, and treatment of chronic diseases like diabetes, asthma, and rheumatoid arthritis. Without effective antibiotics, we lose much of the advancements medical science has made in the the modern era.
Maxwell is now working to solve this global health emergency.